Just a thought.
With the new developments and the hunger in this space this one will not last long, it is a shining value out there to many players that need what they can offer, solid long term sustained strategic growth!!!
Buyout at $4.5 Bill would do IT!! These are huge money makers that will be huge steriod shots for a buyout!! Fred the CEO righted the WHOLE company fixed the Hayward problems and launched their Rytary Proprietary Parkinsons ER profitable drug that could use Mylans reach to really accelerate the precription growth. Keep Fred as a Div CEO as He is a Master in BIOSIM development!! GO for IPXL Seveley Undervalued by them cheap before they rise in value!! $4.5 bill would do it
I get the feeling like proof of concept has happened and now a deal with a major is coming. Someone with expertise to bring Rytary into multiple world markets and illuminate the product. We'll see my feeling is Fred is working thorugh matters beneficially to get them accomplished. I like what I heard in the last Confence call and the q & a with Randall Stanicky. Fred has got it together. Long term plans to make Impax a top ten player in the Generic space, although will listen and do what is in the best interest of the shareholders.
$2.4 bill sales in 2013 not sure what figures are currently sure they are close
Sounds like Renvela in which case Nobody else will get to launch, and Impax will be an authorized generic to Purdue, you out to read that family story some time ;) , then a few months or 8 months later final approval perhaps we get it first again! ;)
Here is the skinny on Oxy: If Impax does not receive final ANDA approval for its generic version, it will still have the right to launch a specified number of bottles of an authorized generic version of OxyContin. In either case, the start date will be Jan. 1, 2016.
The correct spelling is Renvela and Impax was an approved supplier not long ago, so a quick transition into a approved generic supplier of all strengths would make a lot of sense at this point. That's my two cents.
Wilkenson is running a tight ship and even Randall one of the all time top Analyst appreciated what he heard. This is a new company rising!! Grow the business, gain approvals ( Adderal- the big gainers!) and run with it efficiently and don't look back. Use your compass Fred and do what is in the best interest of us the shareholders!! You own a lot of shares too, that's what I like about you, you speak with real interest, not a blow hard nit picky observer!!
This is from yesterday's Dow Jones Newswire: 5:53 pm ET
Bass Says Long Positions Also Include Impax Laboratories Inc., and ZS Pharma Inc.
Both companies would shoot up $10-13 points on the announcement! This would be a great combination. Today LCI Pharma bought a generic for $1.5 Bill that Doubled its size and the stock was up $10 on the announcement. Impax much more valuable, a $4.5 Billion dollar company that could be bought in a stock transaction by Endo and be instantly accretive. They just integrated a $750 Million Private Watson Generic company purchase and have Proprietary Rytary drug launched that is growing scripps nicely and profitably!! It is a 80% margin Proprietary Parkinsons drug!!